Assessment of clinical outcomes in breast cancer patients treated with taxanes: Multi-analytical approach

Gene

Volumn 543, Issue 1, 2014, Pages 69-75

  Tulsyan, Sonam ^a   Chaturvedi, Pankaj ^a   Singh, Abhishek Kumar ^a   Agarwal, Gaurav ^a   Lal, Punita ^a   Agrawal, Sushma ^a   Mittal, Rama Devi ^a   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

ABCB1; Clinical response; Cytochrome P450; Myelosuppression; Polymorphisms

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ADULT; ALLELE; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG TRANSPORT; FEBRILE NEUTROPENIA; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIFACTOR DIMENSIONALITY REDUCTION; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ABCB1; CLINICAL RESPONSE; CYTOCHROME P450; MYELOSUPPRESSION; POLYMORPHISMS;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 84899623343     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.04.004     Document Type: Article

References (32)

1. Abal M., Andreu J.M., Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Current Cancer Drug Targets 2003, 3:193-203.
2. Bosch T.M., Huitema A.D., Doodeman V.D., Jansen R., Witteveen E., Smit W.M., Jansen R.L., van Herpen C.M., Soesan M., Beijnen J.H., Schellens J.H. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clinical Cancer Research 2006, 12:5786-5793.
3. Bournique B., Lemarie A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metabolism and Disposition 2002, 30:1149-1152.
4. Chang H., Rha S.Y., Jeung H.C., Im C.K., Ahn J.B., Kwon W.S., Yoo N.C., Roh J.K., Chung H.C. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of Oncology 2009, 20:272-277.
5. Crown J. Docetaxel: overview of an active drug for breast cancer. The Oncologist 2001, 6(Suppl. 3):1-4.
6. Dong N., Yu J., Wang C., Zheng X., Wang Z., Di L., Song G., Zhu B., Che L., Jia J., Jiang H., Zhou X., Wang X., Ren J. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. Journal of Cancer Research and Clinical Oncology 2012, 138:1197-1203.
7. Edge S.B., Compton C.C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology 2010, 17:1471-1474.
8. Esposito M., Venturini M., Vannozzi M.O., Tolino G., Lunardi G., Garrone O., Angiolini C., Viale M., Bergaglio M., Del Mastro L., Rosso R. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. Journal of Clinical Oncology 1999, 17:1132.
9. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Advanced Drug Delivery Reviews 2002, 54:1295-1310.
10. Gehrmann M., Schmidt M., Brase J.C., Roos P., Hengstler J.G. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?. Pharmacogenomics 2008, 9:969-974.
11. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J., Schuetz E., Lim R., Lim H.L., Ong A.B., Lee H.S. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. Journal of Clinical Oncology 2002, 20:3683-3690.
12. Hahn L.W., Ritchie M.D., Moore J.H. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003, 19:376-382.
13. Hanna I.H., Dawling S., Roodi N., Guengerich F.P., Parl F.F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Research 2000, 60:3440-3444.
14. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., Nuessler A.C., Neuhaus P., Klattig J., Eiselt R., Koch I., Zibat A., Brockmoller J., Halpert J.R., Zanger U.M., Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001, 11:773-779.
15. Kafka A., Sauer G., Jaeger C., Grundmann R., Kreienberg R., Zeillinger R., Deissler H. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003, 22:1117-1121.
16. Kim K.P., Ahn J.H., Kim S.B., Jung K.H., Yoon D.H., Lee J.S., Ahn S.H. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemotherapy and Pharmacology 2012, 69:1221-1227.
17. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski M.S., Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 2001, 27:383-391.
18. Marsh S. Taxane pharmacogenetics. Personalized Medicine 2006, 3:33-43.
19. Marsh S., McLeod H.L. Pharmacogenetics and oncology treatment for breast cancer. Expert Opinion on Pharmacotherapy 2007, 8:119-127.
20. Marsh S., Somlo G., Li X., Frankel P., King C.R., Shannon W.D., McLeod H.L., Synold T.W. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics Journal 2007, 7:362-365.
21. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 1988, 16:1215.
22. Rizzo R., Spaggiari F., Indelli M., Lelli G., Baricordi O.R., Rimessi P., Ferlini A. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Research and Treatment 2010, 124:593-598.
23. Salminen E., Bergman M., Huhtala S., Ekholm E. Docetaxel: standard recommended dose of 100mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. Journal of Clinical Oncology 1999, 17:1127.
24. Shimada T., Watanabe J., Kawajiri K., Sutter T.R., Guengerich F.P., Gillam E.M., Inoue K. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999, 20:1607-1613.
25. Sissung T.M., Mross K., Steinberg S.M., Behringer D., Figg W.D., Sparreboom A., Mielke S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. European Journal of Cancer 2006, 42:2893-2896.
26. Sole X., Guino E., Valls J., Iniesta R., Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006, 22:1928-1929.
27. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2031-2035.
28. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. Journal of Pharmacology and Experimental Therapeutics 2001, 297:1137-1143.
29. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000, 92:205-216.
30. Tran A., Jullien V., Alexandre J., Rey E., Rabillon F., Girre V., Dieras V., Pons G., Goldwasser F., Treluyer J.M. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clinical Pharmacology and Therapeutics 2006, 79:570-580.
31. Tsai S.M., Lin C.Y., Wu S.H., Hou L.A., Ma H., Tsai L.Y., Hou M.F. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clinica Chimica Acta 2009, 404:160-165.
32. Yamaguchi H., Hishinuma T., Endo N., Tsukamoto H., Kishikawa Y., Sato M., Murai Y., Hiratsuka M., Ito K., Okamura C., Yaegashi N., Suzuki N., Tomioka Y., Goto J. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. International Journal of Gynecological Cancer 2006, 16:979-985.